Lv21
120 积分 2021-04-07 加入
Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?
2小时前
求助中
The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma
2小时前
已完结
Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma
4小时前
已完结
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
1个月前
已完结
Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma
2个月前
已完结
The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse
2个月前
已完结
IMiDs New and Old
2个月前
已完结
Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
2个月前
已完结
Progress in targeted therapy for high-risk diffuse large B cell lymphoma
3个月前
已关闭
Progress in targeted therapy for high-risk diffuse large B cell lymphoma
3个月前
已关闭
皖公网安备34019202002308
